Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Inclusion Criteria: * Patients aged 18- 70 years of either gender. * Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included. * Duration of plaque psoriasis for at least 6 months prior to the study. * Psoriasis that has not shown adequate response to topical therapies Exclusion Criteria: * Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis. * Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded. * Known hypersensitivity or contraindications to either methotrexate or tofacitinib. * History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy. * Pregnant or lactating women will not be eligible for the study.